The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Non-Radiographic Axial Spondyloarthritis Therapeutic Market By 2030 Starting From Its 2026 Size?
The non-radiographic axial spondyloarthritis therapeutic market has experienced significant expansion in recent years. Its value is expected to rise from $1.04 billion in 2025 to $1.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.9%. The growth witnessed during the historic period can be attributed to the increasing recognition of non-radiographic axial spondyloarthritis, limitations of conventional NSAID therapy, improved diagnostic criteria adoption, growing rheumatology specialty care access, and the expansion of biologic drug availability.
The therapeutic market for non-radiographic axial spondyloarthritis is projected to experience substantial expansion in the coming years. This market is forecast to reach $1.72 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.6%. This anticipated growth during the forecast period is primarily driven by factors such as the accelerated development of next-generation biologics, the increasing uptake of JAK inhibitor treatments, a heightened emphasis on individualized rheumatology care, the broader implementation of early-stage intervention protocols, and improved patient awareness and diagnosis rates. Key trends foreseen over the forecast period encompass a greater adoption of biologic disease-modifying therapies, an increased utilization of IL-17 and TNF inhibitors, a stronger focus on intervening in the early stages of the disease, the proliferation of targeted small molecule treatments, and a reinforced commitment to long-term disease control.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24627&type=smp
What Drivers Are Shaping The Future Growth Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
The rise in clinical trials is projected to fuel the expansion of the non-radiographic axial spondyloarthritis therapeutic market in the coming years. Clinical trials represent research investigations conducted on humans to evaluate the safety, efficacy, and potential side effects of medical interventions or treatments. The increasing number of these trials is attributed to the growing need for personalized and innovative therapies that demand rigorous testing for both safety and effectiveness. Clinical trials provide crucial support for non-radiographic axial spondyloarthritis therapeutics by offering evidence-based validation of treatment efficacy and safety in the early phases of the disease, thereby facilitating regulatory approvals and broader clinical integration. For example, in December 2024, the Association of the British Pharmaceutical Industry, a UK-based government and NHS organization dedicated to improving patient access to novel treatments, reported a rise in the total number of industry clinical trials initiated in the UK, increasing from 411 trials in 2022 to 426 in 2023. Thus, the escalating number of clinical trials is driving the growth of the non-radiographic axial spondyloarthritis therapeutic market.
Which Segment Categories Define The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
The non-radiographic axial spondyloarthritis therapeutic market covered in this report is segmented –
1) By Type: Non-Steroidal Anti-Inflammatory Drugs, Biologics, Small Molecule Therapies, Corticosteroids
2) By Application: Oral, Injectable, Parenteral
3) By End User: Hospitals, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Non-Steroidal Anti-Inflammatory Drugs: COX-2 Inhibitors, Non-Selective NSAIDs
2) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors
3) By Small Molecule Therapies: Janus Kinase (JAK) Inhibitors, TYK2 Inhibitors
4) By Corticosteroids: Oral Corticosteroids, Intra-Articular Corticosteroid Injections
What Major Market Trends Are Driving Changes In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
Leading companies in the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic sector are focusing on creating novel treatments, such as dual IL-17A/IL-17F biologic inhibitors and user-friendly delivery methods. This focus is driven by increasing diagnosis rates, earlier detection of the disease, the necessity for more rapid and profound inflammatory management, and patients’ desire for less frequent or more convenient dosing regimens. Dual IL-17A/IL-17F biologic inhibitors function as monoclonal antibodies, designed to specifically and simultaneously impede the cytokines IL-17A and IL-17F. This mechanism helps control nr-axSpA symptoms by diminishing inflammation, alleviating pain and stiffness, and slowing structural deterioration. For example, following FDA approval, UCB S.A., a global biopharmaceutical company based in Belgium, introduced BIMZELX in the U.S. in September 2024 for adults suffering from active nr-axSpA. BIMZELX is a humanized IgG monoclonal antibody engineered to neutralize both IL-17A and IL-17F, thereby offering a more comprehensive suppression of IL-17-mediated pathways compared to conventional TNF inhibitors or single-target IL-17 treatments. Beyond its use in nr-axSpA, BIMZELX also holds indications for moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, thus addressing the changing treatment requirements of patients with various inflammatory conditions.
Who Are The Top Companies Competing In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
Major companies operating in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc, Johnson and Johnson, AbbVie Inc, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc, Biogen Inc, Daiichi Sankyo Company Limited, UCB SA, Mochida Pharmaceutical Co Ltd, Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co Ltd, Qyuns Therapeutics Co Ltd, Sandoz Group AG, Boehringer Ingelheim GmbH, Roche Holding AG
Read the full non-radiographic axial spondyloarthritis therapeutic market report here:
Which Geographic Regions Are Influencing Demand In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2025. The regions covered in the non-radiographic axial spondyloarthritis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Radiographic Axial Spondyloarthritis Therapeutic Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24627&type=smp
Browse Through More Reports Similar to the Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market 2026, By The Business Research Company
Diabetic Retinopathy Global Market Report
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report
Proliferative Diabetic Retinopathy Pdr Global Market Report
Diabetic Neuropathy Global Market Report
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model